S63845, either alone or in combination with inhibitors of oncogenic kinases, was found to be moderately effective in certain solid tumours, such as breast cancer and prostate cancer [171, 222] and SCLC derived cell lines that are express high levels of MCL-1 but low levels of BCL-XL [223]. Here, BCL2L1 is linked to breast cancer.